Literature DB >> 17081918

Mechanisms of transcoelomic metastasis in ovarian cancer.

David S P Tan1, Roshan Agarwal, Stanley B Kaye.   

Abstract

Metastasis from epithelial ovarian cancer can occur via the transcoelomic, haematogeneous, or lymphatic route. Of these, transcoelomic metastasis is the most common, and is responsible for the greatest morbidity and mortality in women with this disease. Unfortunately, very little is known about the mechanisms behind this process. This review assesses the current evidence and ideas about the biology of transcoelomic dissemination. The mechanisms of cell detachment, migration, and implantation in transcoelomic metastasis are placed within the context of clinical observations of ovarian cancer to derive a stepwise hypothesis of this process. Evidence for transcoelomic dissemination versus transcoelomic metaplasia in ovarian cancer is presented. Future high throughput microarray studies that compare changes at a genomic and gene expression level between primary ovarian tumours and their peritoneal metastases are hoped to lead to a more conclusive picture of transcoelomic metastasis, and to delineate the key molecular players in this process. These studies might also result in the identification of potential new therapeutic targets in ovarian cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17081918     DOI: 10.1016/S1470-2045(06)70939-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  182 in total

Review 1.  Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression.

Authors:  H Chkourko Gusky; J Diedrich; O A MacDougald; I Podgorski
Journal:  Obes Rev       Date:  2016-07-19       Impact factor: 9.213

2.  Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.

Authors:  Wen-Jane Lee; Keng-Hsin Lan; Chiang-Ting Chou; Yu-Chiao Yi; Wei-Chih Chen; Hung-Chuan Pan; Yen-Chun Peng; Keh-Bin Wang; Yi-Ching Chen; Te-Hsin Chao; Hsing-Ru Tien; Wayne Huey Herng Sheu; Meei-Ling Sheu
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

3.  Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model.

Authors:  Wim Bouquet; Steven Deleye; Steven Staelens; Lieselotte De Smet; Nancy Van Damme; Isabelle Debergh; Wim P Ceelen; Filip De Vos; Jean Paul Remon; Chris Vervaet
Journal:  Pharm Res       Date:  2011-03-18       Impact factor: 4.200

4.  M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis.

Authors:  Alexandre de la Fuente; Lorena Alonso-Alconada; Clotilde Costa; Juan Cueva; Tomas Garcia-Caballero; Rafael Lopez-Lopez; Miguel Abal
Journal:  J Natl Cancer Inst       Date:  2015-07-06       Impact factor: 13.506

5.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

6.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

8.  Fallopian Tube Tumor Mimicking Primary Gastrointestinal Malignancy.

Authors:  Anupam K Gupta; Oscar A Vazquez
Journal:  Cureus       Date:  2020-08-17

9.  Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.

Authors:  Galina Gritsina; Fang Xiao; Shane W O'Brien; Rashid Gabbasov; Marisa A Maglaty; Ren-Huan Xu; Roshan J Thapa; Yan Zhou; Emmanuelle Nicolas; Samuel Litwin; Siddharth Balachandran; Luis J Sigal; Dennis Huszar; Denise C Connolly
Journal:  Mol Cancer Ther       Date:  2015-02-02       Impact factor: 6.261

10.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.